复方利血平氨苯蝶啶片治疗原发性高血压的Meta分析
|
摘要
目的评价应用复方利血平氨苯蝶啶片治疗原发性高血压病的疗效、性价比及安全性。方法计算机检索Cochrane Library、Pubmed、Bio Med Central、中国学术期刊全文数据库、维普数据库、万方数据库,收集复方利血平氨苯蝶啶片治疗原发性高血压病的随机对照试验,按纳入和排除标准由2名评价者独立选择文献,提取资料,交叉核对并进行方法学质量评估,使用Revman5.0软件进行META分析。结果共纳入22项研究,2536例患者。复方利血平氨苯蝶啶片组与钙离子拮抗剂组总有效率之比及其95%可信区间为1.10(0.86~1.41),两组差异无统计学意义(P=0.45);复方利血平氨苯蝶啶片组在控制心率总有效率之比及其95%可信区间为1.25(0.42~2.08),差异有统计学意义(P=0.003);安全性结果:复方利血平氨苯蝶啶片组与钙离子拮抗剂不良事件发生率之差及其95%可信区间为1.13(0.82~1.56),两组差异无统计学意义(P=0.46)。结论根据目前研究证据,复方利血平氨苯蝶啶片与钙离子拮抗剂相比疗效相近、不良事件的发生情况差异不明显,有较为可靠的疗效和安全性。
Objective To evaluate systematically the efficacy,cost performance and safety of Compound Reserpine Triamterene tablets. Methods The databases of Cochrane Controlled Trials Register/CENTRAL,Pubmed,Biomed Central,CJFD,VIP Database and Wangfang Database were retrieved with computers for collecting randomized controlled trials( RCT) about the treatment of hypertention. The RCT were selected by two researchers independently according to inclusion and exclusion criterions and materials were extracted,checked crossly and given methodological quality evalution. The Meta-analysis was conducted by using Rev Man 5. 0 software. Results The 22 studies were eligible for inclusion. As to the efficacy,there was no statistical significant difference between Compound Anti-Hypertensive Tablets and Calcium antagonists( OR = 1. 10,95% CI:0. 86-1. 41,P = 0. 45). It was effective to slow heart rate by persisting in taking medicine of Anti-hypentensive Tablets( OR = 1. 25,95% CI:0. 42-2. 08,P = 0. 003). For the safety,there was also no statistical significant difference between the research drug and the control( OR = 1. 13,95% CI:0. 82-1. 56,P = 0. 46). Conclusion Based on the current evidences,Compound Anti-Hypertensive Tablets appear to have the same effect as calcium antagonists without more adverse events.
Objective To evaluate systematically the efficacy,cost performance and safety of Compound Reserpine Triamterene tablets. Methods The databases of Cochrane Controlled Trials Register/CENTRAL,Pubmed,Biomed Central,CJFD,VIP Database and Wangfang Database were retrieved with computers for collecting randomized controlled trials( RCT) about the treatment of hypertention. The RCT were selected by two researchers independently according to inclusion and exclusion criterions and materials were extracted,checked crossly and given methodological quality evalution. The Meta-analysis was conducted by using Rev Man 5. 0 software. Results The 22 studies were eligible for inclusion. As to the efficacy,there was no statistical significant difference between Compound Anti-Hypertensive Tablets and Calcium antagonists( OR = 1. 10,95% CI:0. 86-1. 41,P = 0. 45). It was effective to slow heart rate by persisting in taking medicine of Anti-hypentensive Tablets( OR = 1. 25,95% CI:0. 42-2. 08,P = 0. 003). For the safety,there was also no statistical significant difference between the research drug and the control( OR = 1. 13,95% CI:0. 82-1. 56,P = 0. 46). Conclusion Based on the current evidences,Compound Anti-Hypertensive Tablets appear to have the same effect as calcium antagonists without more adverse events.
引文
[1]武轶群,何柳,宋岩,等.降压0号治疗原发性高血压有效性和安全性的系统评价[J].中华疾病控制杂志,2009,13(3):225-231.
[2]孙宁玲,吴彦,洪昭光,等.北京降压0号与氨氯地平治疗原发性高血压病的临床对比试验[J].中国社区医师,2013,18(36):24-25.
[3]张成荣,何英鸾.北京降压0号与苯磺酸氨氯地平治疗原发性高血压的疗效比较[J].现代医药卫生,2005,21(21):2882-2883.
[4]张雄辉.北京降压0号和非洛地平缓释片治疗原发性轻中度高血压的疗效分析[J].中国医药指南,2013,11(4):250-251.
[5]朱洪新,高立栋,石俊霞.双利地平片与北京降压0号治疗原发性高血压的疗效比较[J].基层医学论坛,2003,7(8):684-685.
[6]杨菱.北京降压0号与苯磺酸氨氯地平治疗原发性高血压的成本—效果分析[J].山西医药杂志,2005,34(5):423-424.
[7]潘琼,王丽慧.北京降压0号与拜新同治疗高血压病的效价比较[J].中国社区医师(医学专业),2011,13(30):93-94.
[8]陆瑾.用北京降压0号降压片治疗高血压的效果观察[J].当代医药论丛,2014,12(4):263-264.
[9]陈军.北京降压0号与苯磺酸氨氯地平治疗社区原发性高血压的药物依从性比较[J].邯郸医学高等专科学校学报,2006,19(4):277-278.
[10]齐文健.拉西地平与北京降压0号治疗原发性高血压的疗效比较[J].中国冶金工业医学杂志,2003,20(3):178-179.
[11]何朝珠,邹石.北京降压0号治疗原发性高血压病的临床再评价[J].中国临床药理学与治疗学,2002,7(6):548-549.
[12]张利生.老年性高血压患者服用北京降压0号80例疗效观察[J].基层医学论坛,2005,9(1):34-34.
[13]曹新荣.北京降压0号治疗老年人高血压84例临床观察[J].临床医药实践,2002,11(6):450-450.
[14]杨莉莉,赵宇.北京降压0号对高血压病治疗作用的临床观察[J].齐齐哈尔医学院学报,2008,29(6):663-666.
[15]许成勇,王泽川,陈少龙.北京降压0号治疗原发性轻中度高血压临床体会[J].医学综述,2005,11(6):569-570.
[16]赵建萍,王玉霞,伍艳兰,等.北京降压0号治疗原发性高血压的观察[J].辽宁医学院学报,2004,25(3):31-32.
[17]高庆忠,耿丽君,王淑琴.北京降压0号治疗原发性高血压动态监测60例[J].中国煤炭工业医学杂志,2005,8(3):285-286.
[18]吴彦,孙宁玲,洪昭光,等.北京降压0号治疗轻中度原发性高血压的长期疗效观察[J].中华心血管病杂志,2003,31(6):408-412.
[29]顾娜妮,路榕.北京降压0号治疗原发性高血压疗效观察[J].东南国防医药,2005,7(6):435-436..
[20]连海燕.老年高血压患者应用复方利血平氨苯蝶啶片的疗效分析[J].中国农村卫生,2015(22):92-92.
[21]禹晓宁,焦建寅.拜心同(硝苯地平控释片)与复方利血平氨苯蝶啶片降压疗效对比[J].临床合理用药杂志,2011,4(3C):33-34.
[22]郭睿,黄跃洲.复方利血平氨苯蝶定片治疗中老年原发性高血压的临床疗效和安全性分析[J].四川医学,2017,38(3):324-326.
[23]罗春生,宋丽,王月香,等.复方利血平氨苯蝶啶片治疗老年高血压的效果研究[J].中国地方病防治杂志,2017,32(3):316-317.
[2]孙宁玲,吴彦,洪昭光,等.北京降压0号与氨氯地平治疗原发性高血压病的临床对比试验[J].中国社区医师,2013,18(36):24-25.
[3]张成荣,何英鸾.北京降压0号与苯磺酸氨氯地平治疗原发性高血压的疗效比较[J].现代医药卫生,2005,21(21):2882-2883.
[4]张雄辉.北京降压0号和非洛地平缓释片治疗原发性轻中度高血压的疗效分析[J].中国医药指南,2013,11(4):250-251.
[5]朱洪新,高立栋,石俊霞.双利地平片与北京降压0号治疗原发性高血压的疗效比较[J].基层医学论坛,2003,7(8):684-685.
[6]杨菱.北京降压0号与苯磺酸氨氯地平治疗原发性高血压的成本—效果分析[J].山西医药杂志,2005,34(5):423-424.
[7]潘琼,王丽慧.北京降压0号与拜新同治疗高血压病的效价比较[J].中国社区医师(医学专业),2011,13(30):93-94.
[8]陆瑾.用北京降压0号降压片治疗高血压的效果观察[J].当代医药论丛,2014,12(4):263-264.
[9]陈军.北京降压0号与苯磺酸氨氯地平治疗社区原发性高血压的药物依从性比较[J].邯郸医学高等专科学校学报,2006,19(4):277-278.
[10]齐文健.拉西地平与北京降压0号治疗原发性高血压的疗效比较[J].中国冶金工业医学杂志,2003,20(3):178-179.
[11]何朝珠,邹石.北京降压0号治疗原发性高血压病的临床再评价[J].中国临床药理学与治疗学,2002,7(6):548-549.
[12]张利生.老年性高血压患者服用北京降压0号80例疗效观察[J].基层医学论坛,2005,9(1):34-34.
[13]曹新荣.北京降压0号治疗老年人高血压84例临床观察[J].临床医药实践,2002,11(6):450-450.
[14]杨莉莉,赵宇.北京降压0号对高血压病治疗作用的临床观察[J].齐齐哈尔医学院学报,2008,29(6):663-666.
[15]许成勇,王泽川,陈少龙.北京降压0号治疗原发性轻中度高血压临床体会[J].医学综述,2005,11(6):569-570.
[16]赵建萍,王玉霞,伍艳兰,等.北京降压0号治疗原发性高血压的观察[J].辽宁医学院学报,2004,25(3):31-32.
[17]高庆忠,耿丽君,王淑琴.北京降压0号治疗原发性高血压动态监测60例[J].中国煤炭工业医学杂志,2005,8(3):285-286.
[18]吴彦,孙宁玲,洪昭光,等.北京降压0号治疗轻中度原发性高血压的长期疗效观察[J].中华心血管病杂志,2003,31(6):408-412.
[29]顾娜妮,路榕.北京降压0号治疗原发性高血压疗效观察[J].东南国防医药,2005,7(6):435-436..
[20]连海燕.老年高血压患者应用复方利血平氨苯蝶啶片的疗效分析[J].中国农村卫生,2015(22):92-92.
[21]禹晓宁,焦建寅.拜心同(硝苯地平控释片)与复方利血平氨苯蝶啶片降压疗效对比[J].临床合理用药杂志,2011,4(3C):33-34.
[22]郭睿,黄跃洲.复方利血平氨苯蝶定片治疗中老年原发性高血压的临床疗效和安全性分析[J].四川医学,2017,38(3):324-326.
[23]罗春生,宋丽,王月香,等.复方利血平氨苯蝶啶片治疗老年高血压的效果研究[J].中国地方病防治杂志,2017,32(3):316-317.